Skip to main content
YIFAN PHARMACEUTICAL CO.,LTD logo

YIFAN PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 002019 ISIN · CNE000001K65 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,497 across all filing types
Latest filing 2024-03-05 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002019

About YIFAN PHARMACEUTICAL CO.,LTD

https://www.yifanyy.com

Yifan Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and commercialization of innovative biologics, specialty small molecules, and traditional Chinese medicine. The company maintains a diverse product portfolio, notably featuring Ryzneuta (efbemalenograstim alfa), a long-acting recombinant human granulocyte colony-stimulating factor used to treat chemotherapy-induced neutropenia. It is also recognized as a major global supplier of Vitamin B5 (D-calcium pantothenate). Operating with a global perspective, the firm manages integrated R&D and production platforms that adhere to international quality standards. Its core activities span drug discovery, clinical development, and large-scale manufacturing, with a strategic emphasis on therapeutic areas such as oncology, hematology, and dermatology.

Recent filings

Filing Released Lang Actions
关于全资子公司再次通过高新技术企业认定的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement regarding the re-certification of a wholly-owned subsidiary as a high-tech enterprise, including details about the certificate and its impact on tax rates and company performance. It does not contain financial statements, detailed financial data, or comprehensive report content. It is an official company announcement about a regulatory or tax status update, not a full report or detailed financial disclosure. The document length is only 653 characters, indicating it is a brief announcement rather than a full report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-03-05 Chinese
关于全资子公司再次通过高新技术企业认定的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (667 characters) from a company about its wholly-owned subsidiary receiving a renewed high-tech enterprise certificate. It discusses the certificate details, tax benefits, and impact on financials but does not contain any financial statements or detailed financial data. It is an official announcement of a regulatory or compliance nature rather than a full report or detailed financial disclosure. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is not about board changes, voting results, or capital changes. The document is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement that does not fit other specific categories.
2024-02-29 Chinese
关于麻芩消咳颗粒获得新加坡注册批文的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the approval of a new drug registration in Singapore by the Health Sciences Authority (HSA). It details the product information, registration number, and potential impact on the company. The document is short (1040 characters) and serves as a formal announcement of a regulatory approval rather than a financial report or detailed filing. There is no financial data, no mention of annual or quarterly reports, no management changes, no voting results, or other specific report types. It fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement about product registration approval.
2024-02-29 Chinese
关于控股股东部分股份质押及解除质押的公告
Major Shareholding Notification Classification · 100% confidence The document is a public announcement regarding the pledge and release of shares by a controlling shareholder of the company. It details the number of shares pledged, released, and the cumulative pledge status, including dates and parties involved. There is no financial statement, earnings data, or management discussion. The document is a regulatory disclosure about share pledging activities by a major shareholder, which fits the category of Major Shareholding Notification (MRQ). The document length is short and focused solely on share pledge information, not a full report or announcement of a report publication.
2024-02-22 Chinese
关于公司部分董事、高级管理人员及核心人员增持股份计划实施完成的公告
Director's Dealing Classification · 100% confidence The document is an announcement regarding the completion of a share increase plan by certain directors, senior management, and core personnel of the company. It details the number of shares increased, the timing, and compliance with relevant securities laws. There is no financial statement or report content, but rather a disclosure of insider share transactions. This fits the definition of 'Director's Dealing' (DIRS), which covers reports of personal share transactions by company directors and executives (insider trades). The document length is short and focused solely on shareholding changes by insiders, confirming the classification.
2024-02-18 Chinese
关于公司部分董事、高级管理人员及核心人员拟增持公司股份的公告
Director's Dealing Classification · 100% confidence The document is an announcement regarding a planned increase in shareholding by certain company directors, senior management, and core personnel. It details the number of shares held before the plan, the intended amount of shares to be purchased, the timeframe (6 months), and compliance with relevant securities regulations. There are no financial statements, earnings data, or report attachments. The content focuses on insider share transactions and intentions to buy shares, which aligns with the definition of 'Director's Dealing' filings. The document length is under 5,000 characters and is a direct announcement of insider planned share purchases, not a report or certification. Therefore, the appropriate classification is 'DIRS' (Director's Dealing).
2024-02-01 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.